1. Home
  2. SLI vs SDGR Comparison

SLI vs SDGR Comparison

Compare SLI & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard Lithium Ltd.

SLI

Standard Lithium Ltd.

HOLD

Current Price

$3.84

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$12.36

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLI
SDGR
Founded
1998
1990
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
850.5M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
SLI
SDGR
Price
$3.84
$12.36
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$5.25
$21.00
AVG Volume (30 Days)
1.7M
1.2M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.14
EPS
N/A
N/A
Revenue
N/A
$255,869,000.00
Revenue This Year
N/A
$0.76
Revenue Next Year
N/A
$4.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.29
52 Week Low
$1.37
$10.95
52 Week High
$6.40
$27.63

Technical Indicators

Market Signals
Indicator
SLI
SDGR
Relative Strength Index (RSI) 53.21 53.56
Support Level $3.16 $11.03
Resistance Level $4.42 $13.36
Average True Range (ATR) 0.22 0.62
MACD 0.07 0.18
Stochastic Oscillator 70.66 57.64

Price Performance

Historical Comparison
SLI
SDGR

About SLI Standard Lithium Ltd.

Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: